Neurocognitive Effects of Opiate Agonist Treatment
Status:
Completed
Trial end date:
2017-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to (1) compare the effects of buprenorphine and methadone, two
types of opioid addiction treatment, on the ability to think and reason among people addicted
to opiates, and who are either HIV negative or HIV positive; and (2) investigate whether HIV
infection changes the way opioid treatment affects the ability to think and reason. The
investigators hypothesize that there will be (1) significant improvement in thinking and
reasoning ability after starting buprenorphine treatment compared to methadone treatment,
among participants with and without HIV at 2 and 4 months compared to baseline; and (2) HIV
positive participants will demonstrate significant improvement in thinking and reasoning
ability at 2 and 4 months compared to baseline, but that their thinking and reasoning ability
will still be lower than HIV negative participants.
Phase:
Phase 4
Details
Lead Sponsor:
Albert Einstein College of Medicine Albert Einstein College of Medicine of Yeshiva University
Collaborators:
Fordham University Montefiore Medical Center National Institute on Drug Abuse (NIDA)